Repatriation of stable cirrhotic patients from hepatology to the medical home



Drs Christine Luelo, Rick Ward, Mark Swain, Aziz Shaheen, Juan Abraldes (Edmonton) Calgary Zone webinar series Mental health & hot topics

Repatriation of stable cirrhotic patients from hepatology to the medical home






Calgary Zone webinar series Mental health & hot topics

Calgary Zone webinar series: Mental health & hot topics

HEPATOLOGY CAT REFERRAL VOLUME (ALL REASONS)



											_	
												YEAR TOTAL
19-Feb	19-Mar	19-Apr	19-May	19-Jun	19-Jul	19-Aug	19-Sep	19-Oct	19-Nov	19-Dec		2019
306	315	300	324	210	336	277	322	307	297	255		3530
20-Feb	20-Mar	20-Apr	20-May	20-Jun	20-Jul	20-Aug	20-Sep	20-Oct	20-Nov	20-Dec		2020
279	271	143	149	206	221	255	233	202	265	231		2679
21-Feb	21-Mar	21-Apr	21-May	21-Jun	21-Jul	21-Aug	21-Sep	21-Oct	21-Nov	21-Dec		2021
237	330	291	267	326	275	290	272	326	310	294		3495
22-Feb	22-Mar	22-Apr	22-May	22-Jun	22-Jul	22-Aug	22-Sep	22-Oct	22-Nov	22-Dec		2022
262	291	319	284	313	267	307	315	303	682	360		3986
23-Feb	23-Mar	23-Apr	23-May	23-Jun	23-Jul	23-Aug	23-Sep	23-Oct	23-Nov	Dec-23		2023
560	455	245	378	352	356	347	353	355	370	345		4672

HEPATOLOGY CAT WAIT LISTS

HEPATOLOGY CAT WAIT LIST (ALL REASONS) DEMAND FOR SERVICE JANUARY 2016- DECEMBER 2023

 16-Jan
 16-Mar
 16-Apr
 16-May
 16-Jun
 16-Jul
 16-Aug
 16-Sep
 16-Oct
 16-Nov
 16-Dec
 17-Jan
 17-Feb
 17-Mar
 17-Apr


 17-May
 17-Jun
 17-Jul
 17-Aug
 17-Sep
 17-Oct
 17-Nov
 17-Dec
 18-Jan
 18-Apr
 18-Apr
 18-May
 18-Jul
 18-Aug

 18-Sep
 18-Oct
 18-Nov
 18-Dec
 19-Jan
 19-Feb
 19-Mar
 19-Apr
 19-May
 19-Jul
 19-Aug
 19-Sep
 19-Oct
 19-Nov
 19-Dec

 20-Jan
 20-Feb
 20-Mar
 20-Apr
 20-Jun
 20-Jul
 20-Aug
 20-Sep
 20-Oct
 20-Nov
 20-Dec
 21-Jan
 21-Feb
 21-Mar
 21-Apr

 21-May
 21-Jul
 21-Aug
 21-Sep
 21-Oct
 21-Nov
 21-Dec
 22-Jan
 22-Apr
 22-May
 22-Jul
 22-Aug

 22-Sep
 22-Oct
 22-Nov
 22-Dec
 23-Jan
 23-Feb
 23-Mar
 Apr-23
 Jul-23
 Jul-23
 Aug-23
 Sep-23
 Oct-23
 Nov-23
 Dec-23




Calgary Zone webinar series: Mental health & hot topics

Who?

- Stable cirrhotics including:
 - Alcohol-related cirrhosis and continued abstinence
 - \circ Cured hepatitis C

How?

- Repatriation letter to primary care from hepatology with <u>clear directions</u> for:
 - \circ Ongoing care
 - \circ Re-referral, if needed



A) Clinically significant portal hypertension (csPHT):

- csPHT (has been/ has NOT been) diagnosed in your patient.
- Primary prevention of variceal bleeding and/or decompensation event with Carvedilol 6.25 mg bid for life (if SBP > 100 and no contraindications to beta blockade). Treatment has been started by hepatology, and they do not require repeat endoscopy <u>as long as they remain on carvedilol</u>.
- If contraindications existed for beta blockade or patient was intolerant, gastroenterology has already scheduled q 2-3 year follow up EGD. You do not need to arrange.
- If patient becomes intolerant to β blocker/ develops a contraindication, refer back to hepatology with reason for referral listed as "no longer able to use carvedilol – assess for EGD."




B) Routine monitoring for biochemical decompensation with q12 monthly bloodwork:

- Bili (T&D), INR, albumin (measures of liver function) and <u>refer back to specialist</u> if bilirubin increases > ULN, or INR becomes >1.2, or if albumin decreases to < 35.
- In addition, CBC (no diff), AST, ALT, Cr, sodium to allow for calculation of MELD score in case of decompensation or suspicion of clinical worsening.
- For other concerns use specialist advice telephone line (Specialist Link).
- If concern for recurrent alcohol consumption, then consider increased frequency of laboratory testing and referral to AUD pathway for guidance.



C) Hepatocellular cancer (HCC) screening with an abdominal ultrasound

- Performed by community radiology provider every 6 months until the patient is unlikely to benefit from interventions to treat any liver cancer found due to comorbidities (e.g.,: life expectancy < 1 year from other health issues or inability or unwilling to tolerate invasive procedure for HCC). Cirrhotic patients have a 2-3% chance per year of developing a HCC so screening for HCC is warranted.
- Patient has already been enrolled in a surveillance program at time of discharge. You do not need to arrange these exams.
 - <u>Refer back to specialist</u> if diagnostic imaging reports LiRADS 4 or 5 lesion concerning for HCC or radiology recommends surveillance with another modality.



D) General advice that may impact other aspects of their care:

- I. Avoid alcohol, oral NSAIDS, and use narcotics with extreme caution due to high sensitivity to sedating effects of narcotics in cirrhosis.
- II. Atatins OK (rosuvastatin is the statin of choice in cirrhosis due to limited liver metabolism so doses up to 40 mg/day can be used in compensated cirrhosis. If a patient is already on atorvastatin, then the dose must be adjusted for cirrhosis to no more than 40 mg/day. Other statins have been poorly studied in cirrhosis.
- III. Acetaminophen analgesic of choice in liver disease (up to 2 gms total/day).
- IV. Vaccinations -- appropriate as per guidelines.
- V. Osteoporosis prevention as per guidelines (cirrhotic patients are at increased risk for osteoporosis).
- VI. Healthy, balanced diet with protein intake 1.5 g/kg/d and evening snack (details can be found at <u>https://cirrhosiscare.ca/</u>).
- VII. No added salt diet.
- VIII. Consider discontinuing PPI if possible (infection risk increased with PPIs).

FIB-4: LIVER HEALTH

Questions & comments



Calgary Zone webinar series: Mental health & hot topics